Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing
- PMID: 23306542
- DOI: 10.1164/rccm.201207-1204PP
Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating, and fatal lung disease characterized by interstitial fibrosis with decreasing lung volumes and hypoxemic respiratory failure. The prognosis for patients with IPF is poor and the quest to find effective therapies has been unsuccessful. Despite several clinical trials over the past decade, there are no U.S. Food and Drug Administration-approved treatments for patients with IPF and thus no standard of care. In terms of pathogenesis, IPF is characterized by alveolar epithelial cell injury and activation with interstitial inflammation, fibroblast proliferation with extracellular matrix collagen deposition, and loss of lung function. Because mesenchymal stem cells (MSCs) home to sites of injury, inhibit inflammation, and contribute to epithelial tissue repair, their use has been suggested as a therapy for the treatment of IPF. MSCs have potential as a novel therapeutic agent in multiple diseases and they have been safely administered in a number of clinical trials. Some, but not all, preclinical studies in animal models of lung fibrosis suggest that MSCs might be effective in the treatment of IPF. Given the safety and ease of MSC administration in other patient populations, the results in preclinical animal models of IPF, and the major need for novel therapeutic options in this devastating disease, we propose that carefully designed clinical trials of MSCs for the treatment of patients with IPF are appropriate. Establishing safety in the setting of IPF is the first priority in early clinical trials followed by clinical and biological measures of efficacy.
Comment in
-
Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2013 Jul 15;188(2):251-2. doi: 10.1164/rccm.201301-0072LE. Am J Respir Crit Care Med. 2013. PMID: 23855695 No abstract available.
-
Idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.Am J Respir Crit Care Med. 2013 Jul 15;188(2):252-3. doi: 10.1164/rccm.201301-0192LE. Am J Respir Crit Care Med. 2013. PMID: 23855696 No abstract available.
-
Reply: idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.Am J Respir Crit Care Med. 2013 Jul 15;188(2):253-4. doi: 10.1164/rccm.201302-0244LE. Am J Respir Crit Care Med. 2013. PMID: 23855697 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous